Bariatric surgery can reduce the risk of melanoma

Share This Post

In addition to rapid and lasting weight loss and other health benefits, bariatric surgery is now associated with a 61% reduced risk of malignant melanoma, which is the deadliest skin cancer most closely associated with excessive sun exposure.

The new study will be released on Thursday at the European Obesity Conference in Vienna, Austria. The study also found that the risk of skin cancer in people undergoing bariatric surgery generally decreased by 42%. Among a group of 2,007 obese participants undergoing bariatric surgery in Sweden, the median follow-up period was 18 years.

In this study, subjects who chose surgery as an obesity treatment were compared with 2,040 obese Swedes. The control group had similar basic conditions as the surgical patients, including age, gender, height, cardiovascular risk factors, and psychological Social variables and personality traits, but no cuts.

A research team led by Magdalena Taube from the University of Gothenburg in Sweden believes that changing the risk of melanoma in subjects is deep weight loss. This finding supports the notion that obesity is a risk factor for melanoma, and shows that weight loss in obese patients can reduce the risk of increasing fatal cancer in many countries for decades.

The American Cancer Society estimates that in 2018, about 91,270 new melanomas will be diagnosed in the United States, with 55,150 males and 36,120 females. About 9,320 people will die from the disease. The organization also reported a recent increase in the incidence of melanoma: between 2008 and 2018, the number of new melanoma cases diagnosed each year increased by 53%.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy